Table 4.
Treatment |
|||
---|---|---|---|
Gene | Sex | CON | CORT |
PR | Male | 1.26 ± 0.17 | 1.03 ± 0.18 |
Female | 1.07 ± 0.16 | 1.20 ± 0.27 | |
AR | Male | 1.15 ± 0.10 | 1.13 ± 0.13 |
Female | 1.07 ± 0.15 | 1.54 ± 0.23 | |
ER-α | Male | 1.14 ± 0.14 | 1.06 ± 0.12 |
Female | 1.17 ± 0.25 | 1.50 ± 0.19 | |
MyoD | Male | 1.02 ± 0.05 | 0.96 ± 0.07 |
Female | 1.03 ± 0.09 | 1.12 ± 0.07 | |
MyoG | Male | 1.07 ± 0.11 | 1.17 ± 0.12 |
Female | 1.04 ± 0.10 | 1.15 ± 0.15 | |
Pax-7 | Male | 1.07 ± 0.04 | 1.02 ± 0.04 |
Female | 1.02 ± 0.08 | 1.15 ± 0.07 | |
PPARγ | Male | 0.82 ± 0.08 | 0.96 ± 0.18 |
Female | 1.06 ± 0.14 | 0.79 ± 0.04 | |
CEBP/β | Male | 1.25 ± 0.11a | 1.40 ± 0.18b |
Female | 1.11 ± 0.19a | 1.76 ± 0.24b |
Samples consist of pooled left and right breast muscle, which were obtained from birds at hatch (n = 32). Values are normalized average relative mRNA expression ± SEM.
Means with different superscripts are significantly different between treatments groups (CON/CORT).